bioAffinity Technologies
BIAFW
5 hedge funds and large institutions have $115K invested in bioAffinity Technologies in 2022 Q4 according to their latest regulatory filings, with 0 funds opening new positions, 1 increasing their positions, 2 reducing their positions, and 1 closing their positions.
0.76% less ownership
Funds ownership: 4.05% → 3.29% (-0.76%)
17% less funds holding
Funds holding: 6 → 5 (-1)
50% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 2
99% less capital inflows, than outflows
Capital inflows: $424 | Capital outflows: $41.2K
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$424 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Boothbay Fund Management
New York
|
-$36K |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$5.13K |
| 3 |
Clear Street
New York
|
-$44 |
BIAFW Hedge Fund Activity: Q4 2022 in Review
5 of the 6,244 institutional investors tracked by Wall St. Rank reported a position in bioAffinity Technologies (BIAFW) for Q4 2022, worth a combined $115K — down 16% from $137K a quarter earlier.
Sellers outnumbered buyers: 1 fund closed out of BIAFW and 0 opened new positions — a net loss of 1 holder — while 2 trimmed existing stakes and 1 added.
The largest buyer was Susquehanna International Group, adding an estimated $424. The largest seller was Boothbay Fund Management, exiting entirely with an estimated $36K sold.
- 5 institutional investors held bioAffinity Technologies (BIAFW) as of Q4 2022, down from 6 in Q3 2022.
- Funds reported $115K of bioAffinity Technologies stock for Q4 2022, down 16% quarter-over-quarter.
- 0 funds opened new bioAffinity Technologies positions in Q4 2022 and 1 closed out, a net change of -1 holder.
- The largest bioAffinity Technologies buyer in Q4 2022 was Susquehanna International Group, an estimated $424 added.
- The largest bioAffinity Technologies seller in Q4 2022 was Boothbay Fund Management, an estimated $36K sold.
Based on aggregated 13F filings for Q4 2022.